No deaths, seizures or memory loss have been associated with tDCS in over 35 000 stimulation sessions.
tDCS has mostly been used for adult population, but in their comprehensive review, Palm and colleagues concluded that tDCS seems to be safe for pediatric population as well. The method is well tolerated and not associated with serious side-effects or withdrawal effects.
Sooma provides training for new users. For more details on safety, see the ‘Safety’ section on the Science-page.
tDCS has been shown to significantly reduce depression symptoms and bring clinically meaningful results. The effect size is estimated to be similar to antidepressant medication in primary care. Most investigated patient group is adults with moderate to severe depression. Due to its safety, tDCS can also be a viable tool for early intervention in depression.
More detailed information on clinical research and efficacy can be found on the Science-page.
Use in home healthcare environment
The safety of self-administered treatment with Sooma tDCS has been confirmed in clinical studies (Hyvärinen 2016).
The first session should always be done under the supervision of a clinician. During this session, the patient’s ability to perform self-administered stimulation is assessed. After the first session, the treatment device is lent to the patient for the acute treatment phase. If practical, the patient can take pictures of treatment preparations to allow his physician to ensure that self-administered treatment has been done correctly. The device counts the number of treatments done, so that the physician can ensure correct use frequency.
After the acute phase, the device is returned to the clinic, and the patient visits the clinic normally for maintenance treatments.
The device can also be set to lock itself from further use after a set amount of treatments to prevent overuse.